Charles M. Perou

Fondatore presso GeneCentric Therapeutics, Inc.

Consumer Services

Health Technology

Profilo

Charles M.
Perou is the founder of GeneCentric Therapeutics, Inc. which was founded in 2011.
He is currently a Member at The University of North Carolina at Charlotte since 2000.
Dr. Perou holds a doctorate degree from the University of Utah and an undergraduate degree from Bates College.

Posizioni attive di Charles M. Perou

Società	Posizione	Inizio
GeneCentric Therapeutics, Inc. GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC.	Fondatore	01/01/2011
The University of North Carolina at Charlotte	Corporate Officer/Principal	01/01/2000

Tutte le posizioni attive di Charles M. Perou

Formazione di Charles M. Perou

Bates College	Undergraduate Degree
University of Utah	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Charles M. Perou

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
GeneCentric Therapeutics, Inc. GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC.	Health Technology